| Not Yet Recruiting | Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms NCT07499635 | Assiut University | — |
| Not Yet Recruiting | Expression of CD274 (PD-L1) and CD276 in B-cell Malignancies: A Study by Flowcytometry NCT07515313 | Assiut University | — |
| Not Yet Recruiting | Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) NCT07166549 | University Hospital, Basel, Switzerland | Phase 1 |
| Not Yet Recruiting | A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With C NCT07503353 | Sheba Medical Center | Phase 1 / Phase 2 |
| Recruiting | A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymp NCT07271667 | Curis, Inc. | Phase 2 |
| Recruiting | A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With C NCT07135466 | Sheba Medical Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection NCT07332663 | Sichuan University | EARLY_Phase 1 |
| Recruiting | Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies NCT07349849 | Xinqiao Hospital of Chongqing | EARLY_Phase 1 |
| Recruiting | Combination CAR-T Cell Therapy Targeting Hematological Malignancies NCT03125577 | Shenzhen Geno-Immune Medical Institute | Phase 1 / Phase 2 |
| Recruiting | JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies NCT07065279 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | N/A |
| Recruiting | A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Maligna NCT03050190 | Shenzhen Geno-Immune Medical Institute | Phase 1 / Phase 2 |
| Recruiting | Evaluation of SYS6005 in Patients With Advanced Malignant Tumor NCT06958679 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1 |
| Recruiting | A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subje NCT06542250 | AstraZeneca | Phase 1 / Phase 2 |
| Not Yet Recruiting | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infu NCT06519344 | Shanghai Tongji Hospital, Tongji University School of Medicine | EARLY_Phase 1 |
| Active Not Recruiting | Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients NCT06576102 | Maddalena Giannella | — |
| Recruiting | Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients. NCT06375161 | Shanghai Tongji Hospital, Tongji University School of Medicine | EARLY_Phase 1 |
| Recruiting | 4SCAR19U T Cells Targeting B Cell Malignancies NCT05995015 | Shenzhen Geno-Immune Medical Institute | Phase 1 |
| Recruiting | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies NCT05618028 | AbbVie | Phase 1 |
| Recruiting | A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies NCT05683717 | TransThera Sciences (Nanjing), Inc. | Phase 1 |
| Recruiting | CD19/70 Bi-specific CAR-T Cell Therapy NCT05436496 | Shenzhen Geno-Immune Medical Institute | Phase 1 / Phase 2 |
| Recruiting | CD19/79b Bi-specific CAR-T Cell Therapy NCT05436509 | Shenzhen Geno-Immune Medical Institute | Phase 1 / Phase 2 |
| Recruiting | CD19/22 Bi-specific CAR-T Cell Therapy NCT05432882 | Shenzhen Geno-Immune Medical Institute | Phase 1 / Phase 2 |
| Unknown | Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies NCT05275504 | TransThera Sciences (Nanjing), Inc. | Phase 1 |
| Completed | Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malign NCT04551963 | BeiGene | Phase 1 |
| Active Not Recruiting | Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in NCT04509700 | Incyte Corporation | Phase 2 |
| Active Not Recruiting | Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies NCT04170283 | BeiGene | Phase 3 |
| Terminated | Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib NCT03701438 | Gilead Sciences | — |
| Unknown | Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies NCT03642496 | First Affiliated Hospital Xi'an Jiaotong University | EARLY_Phase 1 |
| Completed | A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjec NCT02018861 | Incyte Corporation | Phase 1 / Phase 2 |
| Terminated | Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therap NCT02457598 | Gilead Sciences | Phase 1 |
| Completed | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in NCT02327078 | Incyte Corporation | Phase 1 / Phase 2 |
| Completed | Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies NCT02343120 | BeiGene | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies NCT01905813 | Incyte Corporation | Phase 1 |
| Completed | Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma NCT01775631 | Bristol-Myers Squibb | Phase 1 |
| Completed | A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies NCT00983619 | MedImmune LLC | Phase 1 / Phase 2 |
| Terminated | A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation NCT00672152 | Michael Morse, MD | Phase 1 |